Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by...

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Aberrant protein phosphorylation networks are common in cancer, leading to resistance against tyrosine kinase inhibitors.
• Monitoring signal transduction pathway activity is critical for evaluating drug efficacy and resistance mechanisms.
• Current methods like expression profiling and proteomics have limitations in assessing pathway activity via post-translational modifications.

Purpose of the Study:

• To explain antibody arrays as a tool for identifying system-wide alterations in protein post-translational modifications, particularly phosphorylation.
• To highlight the clinical challenge of monitoring drug treatment success and resistance in cancer patients.
• To discuss the advantages and limitations of antibody arrays in this context.

Main Methods:

• Detailed explanation of antibody array technology for interrogating post-translational modifications.
• Comparison with other methods like microarrays and proteomics.
• Discussion of antibody array accessibility, speed, and limitations.

Main Results:

• Antibody arrays can identify system-wide changes in post-translational modifications, such as phosphorylation.
• These arrays are accessible, do not require expert knowledge or costly equipment, and provide rapid results.
• A key limitation is the availability of arrays targeting diverse post-translational modifications.

Conclusions:

• Antibody arrays are a valuable and practical tool for assessing post-translational modifications in clinical settings.
• They aid in understanding cancer drug response and resistance by characterizing signaling pathway alterations.
• While phosphoproteomics is suited for novel discoveries, antibody arrays are ideal for well-characterized targets.